Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cavet, J.
Right arrow Articles by Middleton, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cavet, J.
Right arrow Articles by Middleton, P. G.
Related Collections
Right arrow Transplantation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 1 September 2001, Vol. 98, No. 5, pp. 1594-1600

TRANSPLANTATION

Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation

James Cavet, Anne M. Dickinson, Jean Norden, Penelope R. A. Taylor, Graham H. Jackson, and Peter G. Middleton

From the University Department of Haematology, School of Clinical and Laboratory Sciences, The Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.


    Abstract
Top
Abstract
Introduction
Patients, materials, and...
Results
Discussion
References

Proinflammatory cytokines including interferon-gamma (IFNgamma ), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNFalpha ) are implicated in the pathogenesis of acute graft-versus-host disease (aGVHD). Cytokine gene polymorphism is associated with functional differences in cytokine regulation and altered clinical performance in a variety of diseases. Polymorphism in the IFNgamma Intron1 microsatellite (CA)n repeat has been linked with in vitro IFNgamma production and renal transplant rejection. The IL-6-174(G/C) single nucleotide polymorphism has been linked to in vitro and in vivo IL-6 production, juvenile chronic arthritis, and renal transplant rejection. This study examined the potential association of GVHD with IFNgamma and IL-6 polymorphisms in 80 sibling bone marrow transplant (BMT) donor/recipient pairs. Patients homozygous for the IFNgamma Intron1 allele 3 had more severe (grade III-IV) aGVHD. Patients possessing the IL-6-174G allele had a trend toward higher grades of aGVHD, and those homozygous for the IL-6-174G allele were more likely to develop chronic GVHD (cGVHD). The associations of previously identified aGVHD severity-associated cytokine gene polymorphisms (TNFd and IL-10-1064) with severe aGVHD were reconfirmed. Logistic regression analysis confirmed the association of severe aGVHD with recipient genotype at IFNgamma Intron1 (odds ratio [OR] 3.92; P = .02), IL-10-1064 (OR 4.61; P = .026) and TNFd (OR 3.29; P = .039), and that of cGVHD with recipient IL-6-174 genotype (OR 4.25; P = .007), in addition to age, gender mismatch, and underlying disease. Assessment of cytokine genotype may potentially allow more accurate prediction of GVHD and appropriate adjustment of GVHD prophylaxis, as well as indicating novel areas for future studies of GVHD pathogenesis. (Blood. 2001;98:1594-1600)

© 2001 by The American Society of Hematology.

    Introduction
Top
Abstract
Introduction
Patients, materials, and...
Results
Discussion
References

Graft-versus-host disease (GVHD) is the most common serious complication of allogeneic bone marrow transplantation (BMT) and severe (grade III-IV) acute GVHD (aGVHD) causes increased mortality.1 However immunosuppressive prophylaxis for GVHD increases infection and decreases the graft-versus-malignancy effect.2 Established risk factors for aGVHD include histoincompatibility, age, sex mismatch, viral status, and prophylaxis,1 whereas chronic GVHD (cGVHD) is largely predicted by prior aGVHD.3 Currently there are no widely established approaches to individualized prediction of GVHD. Proinflammatory cytokines including interferon-gamma (IFNgamma ), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNFalpha ) are important mediators and regulators of GVHD.4,5 The anti-inflammatory and immunomodulatory cytokine IL-10 is associated with transplantation tolerance6 and decreased GVHD.7,8

In human clinical BMT, a large number of T-cell clones produce IFNgamma ,9 whereas levels of IFNgamma increase both before and during aGVHD.10,11 IFNgamma is also implicated as a mediator of aGVHD in a human skin explant model of GVHD, especially in combination with TNFalpha .12 Murine models suggest that IFNgamma may also play a down-regulatory role in aGVHD.13-15 Increased serum IFNgamma 16 and in situ IFNgamma transcription have also been demonstrated in cutaneous cGVHD.17 The IFNgamma gene (IFNG) maps to chromosome 12p24 and has a (CA)n repeat element within the first intron.18 This microsatellite has 2 common alleles, 2 and 3, which exhibit significant differences in IFNgamma production in vitro; allele 2 associates with greater IFNgamma production than other alleles from mitogen-stimulated peripheral blood mononuclear cells.19,20 The IFNgamma Intron1 microsatellite has shown association with a variety of autoimmune and alloimmune disease states, including lung transplant fibrosis21 and renal transplant rejection.22

Serum IL-6 levels increase during aGVHD,23 correlating with severity24,25 and prognosis,26 and also are elevated in cGVHD.16 The IL6 gene maps to chromosome 7p21,27 and in the promoter region at position -174 a (G/C) single nucleotide polymorphism (SNP) is found close to a glucocorticoid-response element. The IL-6-174C allele associates with lower in vitro and in vivo production, and IL-6-174CC homozygosity is underrepresented in juvenile chronic arthritis.28 Recently the IL-6-174(G/C) SNP genotype of renal transplant donors has been shown to associate significantly with the incidence and severity of acute rejection.29 Just 3' to the IL6 gene is an AT-rich minisatellite30 with variable repeat numbers; this polymorphism has been shown to associate with disease states including osteoporosis31 and systemic lupus erythematosus.32

We have previously demonstrated that homozygosity for the putative high TNFalpha -producer genotype TNFd3 (TNFd3/d3) associates with grade III to IV aGVHD in cyclosporin A (CyA)-treated HLA-matched sibling BMT.33 Possession of one or more IL-10-1064 microsatellite alleles with a high repeat number (i[12-16]) by the recipient also associated with grades III to IV aGVHD in this cohort.33 The association of IL-10-1064i[12-16] alleles with severe aGVHD has been confirmed in HLA-matched sibling recipients given methotrexate (MTX) in addition to CyA prophylaxis.34 Similar associations of TNFd and IL-10-1064i[12-16] alleles with aGVHD severity have been observed in HLA-mismatched cord blood transplants.35 The combination of genetic risk factors in alloimmune processes has been previously suggested as a means of predicting outcome in renal transplantation.22,36 The current study was designed to test the association of GVHD with candidate IFNgamma and IL-6 genotypes in an extended HLA-matched sibling BMT cohort. It was hypothesized that presence of functional polymorphism in the genes of these candidate cytokines would predispose toward differences in aGVHD and cGVHD. Also we wished to assess the relative risk of these cytokine genotypes with respect to established risk factors for GVHD.


    Patients, materials, and methods
Top
Abstract
Introduction
Patients, materials, and...
Results
Discussion
References

Characteristics of the BMT patient cohort

Archival DNA samples from 80 nonpediatric (mean age, 29.18 years; SD, 8.88) sibling BMT recipient and donor pairs were studied. All patients underwent transplantation between 1984 and 1997 for hemopoetic malignancy, with acute leukemia (36 acute myeloid leukemia [AML] and 19 acute lymphocytic leukemia [ALL] patients) and chronic myeloid leukemia (CML, 19 patients) being the most common underlying diagnoses. Fifty-two of the recipients and 44 of the donors were men, with 22 male recipients receiving marrow from a female donor. Thirty-three recipients and 35 donors were positive for cytomegalovirus (CMV) by serology prior to BMT.

Conditioning schedules were those appropriate to the disease, remission status, and prior treatment; after 1990, chemotherapy schedules contained melphalan (3 mg/kg) in place of cyclophosphamide (60 mg/kg × 2). Conditioning comprised cyclophosphamide followed by fractionated total body irradiation (TBI; total 1200 cGy in 6 fractions at 25 cGy/min) in 42 patients, melphalan and TBI in 21 patients, and combined cyclophosphamide, melphalan, and TBI for 1 patient. Busulphan (16 mg/kg) was administered in place of TBI for patients who had previously undergone radiation therapy, together with cyclophosphamide in 9 patients, and busulphan with melphalan in 6 patients. One patient with hypoplastic myelodysplasia received cyclophosphamide alone.

HLA matching had been performed serologically for HLA-A and -B antigens and by high-resolution molecular typing for HLA-DRB1. All grafts were non-T cell depleted and GVHD prophylaxis consisted of 3 mg/kg CyA in all patients. Patients at high risk for GVHD, as determined by skin explant assay,37 advanced age, or multiparous female donor, also received either "short course" MTX38 (n = 17) or corticosteroids (n = 5). All genotypes were determined with the investigator blinded to clinical outcomes. All patients had given informed consent for participation in the study as approved by the local ethics committee.

IFNgamma Intron1 (CA)n microsatellite genotype

IFNgamma Intron1 microsatellite genotypes were determined by polymerase chain reaction (PCR) using 1 µM of each primer,19 0.5 U Taq polymerase (Bioline, London, United Kingdom), 200 µM dNTP mixture, 2.5 mM MgCl2 in 1 × KCl buffer (Bioline) in addition to test DNA, to a final volume of 25 µL. PCR was for 30 cycles at 94°C for 30 seconds, 60°C for 60 seconds, and 72°C for 60 seconds, followed by a final extension of 72°C for 7 minutes. PCR products were resolved by polyacrylamide gel electrophoresis (8%; 19:1 acrylamide to bisacrylamide) and visualized by silver staining.

IL-6-174(G/C) SNP genotype

The IL-6-174(G/C) SNP genotypes were determined in an allele-specific PCR. Primers were GAGCTTCTCTTTCGTTCC and either CCCTAGTTGTGTCTTGCC or CCCTAGTTGTGTCTTGCG. Reactions contained 1 µM of each primer, 0.5 U Taq polymerase (Bioline), 200 µM dNTP mixture, and 1.5 mM MgCl2 in 1 × KCl buffer (Bioline) in addition to test DNA, to a final volume of 25 µL. Amplification was performed on PerkinElmer thermal-cycler (Norwalk, CT) with 30 cycles of 94°C for 30 seconds, 54°C for 60 seconds, and 72°C for 60 seconds, followed by a final extension of 72°C for 7 minutes. PCR products were resolved by agarose gel electrophoresis (2%) and visualized by ethidium bromide.

IL-6 3' (AT)-rich minisatellite genotype

The IL-6 3' (AT)-rich minisatellite genotypes were determined in a PCR reaction containing 1 µM of each primer,32 0.5 U Taq polymerase (Bioline), 200 µM dNTP mixture, and 2 mM MgCl2 in 1 × NH4 buffer (Bioline) in addition to test DNA, to a final volume of 60 µL. Following a "hot start," the PCR cycle was as for the IFNgamma method above. PCR products were resolved by polyacrylamide gel electrophoresis (4%; 19:1 acrylamide to bisacrylamide) and visualized by silver staining.

TNFd microsatellite genotype and IL-10-1064/-1082 haplotypes

Genotypes for the TNFd microsatellite polymorphism were determined as previously described.39 IL-10 haplotypes were determined in an IL-10-1082 SNP allele-specific PCR that coamplifies and reports the linked IL-10-1064 microsatellite repeat.34

Statistical analysis

Univariable analysis of data were by ANOVA using Kruskal-Wallis test, including F test analysis of group variances. Survival estimation by Kaplan-Meier analysis, together with bivariable and multivariable forward stepwise logistic regression analysis was performed using SPSS software (version 9; Chicago, IL). P values less than .05 were regarded as statistically significant, and those between .05 and .1 as indicative of a trend.


    Results
Top
Abstract
Introduction
Patients, materials, and...
Results
Discussion
References

Clinical outcomes

Four additional patients, who had been genotyped, died prior to day 30 without significant aGVHD and were not analyzed for this outcome. Patients who survived more than 30 days from BMT, or who died prior to 30 days with significant GVHD (grades II-IV) were considered assessable for aGVHD (grading by Glucksberg criteria40). Fifteen of the 80 assessable patients did not develop aGVHD; 27 patients developed grade I, 22 grade II, 11 grade III, and 5 grade IV aGVHD. A further 8 patients died prior to day 100 without cGVHD; overall, the day 100 transplantation-related mortality rate was 22.6% (range, 18.0%-27.2%). Patients who survived more than 100 days from BMT were considered assessable for cGVHD (grading by Atkinson et al41). Thirty of 72 assessable patients developed cGVHD. The presence of aGVHD correlated with cGVHD risk. Two of 15 patients surviving at least 100 days without aGVHD developed de novo cGVHD, whereas 28 of 57 with grades I to IV aGVHD went on to develop cGVHD. At day 180, the GVHD mortality rate was 10.7% (range, 8.7%-12.7%) comprising 7 aGVHD-related and 2 cGVHD-related deaths (with 1 subsequent cGVHD-related death at 35 months), and non-GVHD mortality was 15.5% (range, 12.7%-18.3%).

Allele frequencies

Genotyping at the IL-6 (AT)-rich minisatellite showed the following allele frequencies: allele A and B both, f = 0.021; allele C, f = 0.148; allele D, f = 0.281; allele E, f = 0.310; allele F, f = 0.472. These frequencies differ from previously reported frequencies in white populations,32 although they are closest to those of a United Kingdom population.31 In this BMT cohort all other polymorphisms examined displayed allele frequencies similar to those previously published.19,28,34,42,43

IFNgamma genotype and GVHD

Recipient IFNgamma Intron1-3/3 homozygous genotype was significantly associated with more severe aGVHD. Eight (38.1%) of 21 recipients possessing IFNgamma Intron1-3/3 genotype developed grades III to IV aGVHD, whereas 8 (13.6%) of 59 recipients with other alleles developed grades III to IV aGVHD (Tables 1 and 5). Donor genotype did not associate with aGVHD (Table 2); neither were recipient nor donor IFNgamma Intron1 polymorphisms associated with cGVHD.

                              
View this table:
[in this window]
[in a new window]
  		Table 1. Acute GVHD grade and recipient genotype


                              
View this table:
[in this window]
[in a new window]
  		Table 2. Acute GVHD grade and donor genotype

IL-6 genotype and GVHD

Recipients possessing an IL-6-174G allele showed a strong trend toward development of higher grades of aGVHD than those with other genotypes, but not a significant increase in severe aGVHD (Tables 1 and 5). Recipients possessing an IL-6-174G allele had a nonsignificantly increased incidence of cGVHD, whereas IL-6-174GG homozygotes had a substantially greater incidence of cGVHD than recipients with other genotypes. Fifteen (65.2%) of 23 IL-6-174GG homozygotes developed cGVHD, compared to 15 (30.6%) of 49 recipients with a IL-6-174C allele (Tables 3 and 7). No significant relationship between donor IL-6-174 genotype and aGVHD was demonstrated (Table 2), but donor IL-6-174GG homozygous genotype exhibited a strong trend toward increased frequency of cGVHD. Ten (66.7%) of 15 patients with IL-6-174GG homozygous donors developed cGVHD compared to 13 (37.1%) of 35 patients whose donors had an IL-6-174C allele (Tables 4 and 7). There was no association of the IL-6 3' minisatellite of recipient or donor with aGVHD or cGVHD (data not shown).

                              
View this table:
[in this window]
[in a new window]
  		Table 3. Chronic GVHD and recipient genotype


                              
View this table:
[in this window]
[in a new window]
  		Table 4. Chronic GVHD and donor genotype

Recipient TNF genotype and GVHD

TNFd3/d3 homozygous genotype (shared by HLA-matched recipient and donor due to the TNF gene locus position within the major histocompatibility complex class III region) associated with severe aGVHD. Nine (33.3%) of 27 patients with TNFd3/d3 genotype developed grades III to IV aGvHD, whereas only 7 (13.2%) of 53 patients not homozygous for the TNFd3 allele did so (Tables 1 and 6).

Recipient IL-10 genotype and GVHD

Possession of one or more IL-10-1064i[12-16] alleles by the recipient associated significantly with overall aGVHD severity (Tables 1 and 5). Recipients possessing IL-10-1064i[12-16] alleles were at significantly higher risk of severe aGVHD. Thirteen (29.5%) of 44 recipients possessing an IL-10-1064i[12-16] allele developed severe aGVHD, compared to 3 (8.3%) of 36 who possessed only IL-10-1064i[7-11] alleles (Tables 1 and 6).

                              
View this table:
[in this window]
[in a new window]
  		Table 5. Association of genotype with overall acute GVHD grade


                              
View this table:
[in this window]
[in a new window]
  		Table 6. Association of genotype with severe acute GVHD

Other polymorphisms tested

By contrast, no associations were found between GVHD and a number of other polymorphisms, which have been implicated as genetic risk factors in other diseases with immunoregulatory abnormalities: TNFbeta 1 (NcoI-AspHI haplotype),44 CTLA4 (3' AnTn microsatellite),45 TGFbeta 1 (-509 promoter region polymorphism).46 In each case polymorphic alleles showed similar frequency (ie, were similarly distributed) in both aGVHD and cGVHD groups, both for the patient and donor genotypes (data not shown).

Logistic regression analysis of risk factors for GVHD

Logistic regression confirmed the independent association of recipient IFNgamma Intron1-3/3 homozygous genotype with severe aGVHD, together with recipient possession of one or more IL-10-1064i[12-16] alleles and TNFd3d3 homozygous genotype (Table 8). In addition to these genotypic factors, age was also significantly associated with severe aGVHD; forward stepwise modeling implicated recipient IFNgamma , IL-10, and TNF genotypes in addition to age as aGVHD risk factors. IL-6-174GG genotype was confirmed as a risk factor for cGVHD, together with age, gender mismatch (donor female and recipient male), and disease (CML), which have previously been reported as risk factors for cGVHD47 (Table 9). Forward stepwise modeling implicated age, IL-6 genotype, and gender mismatch as cGvHD risk factors.

                              
View this table:
[in this window]
[in a new window]
  		Table 7. Association of genotype with chronic GVHD


                              
View this table:
[in this window]
[in a new window]
  		Table 8. Analysis of risk factors for severe acute GVHD


                              
View this table:
[in this window]
[in a new window]
  		Table 9. Analysis of risk factors for chronic GVHD


    Discussion
Top
Abstract
Introduction
Patients, materials, and...
Results
Discussion
References

Earlier studies have shown that BMT recipients' possession of certain cytokine gene polymorphism alleles is associated with aGVHD and other inflammatory complications of BMT.33,34 The results of this extended study are consistent with this concept and further demonstrate other candidate gene polymorphisms, which show cumulative effects, as well as demonstrating correlation between cytokine genotype and cGVHD.

Recipients homozygous for IFNgamma Intron1 allele 3 (linked to lower in vitro IFNgamma production by stimulated peripheral blood mononuclear cells) were more likely to develop severe aGVHD. Chronic GVHD showed no trend toward association with recipient or donor IFNgamma Intron1 genotype in this study, despite cGVHD largely following prior aGVHD. The finding of a recipient genotype linked in other studies to low in vitro IFNgamma production associating with more severe aGVHD may have 2 possible explanations. First, it has been suggested that IFNgamma may act in a negative feedback regulatory role, as seen in some mouse model studies of GVHD; twice weekly injections of IFNgamma in a subacute murine model of GVHD prevented aGVHD, decreasing intestinal lesions and increasing survival.13 This was associated with a reduction in IFNgamma -producing T cells, suggesting that exogenous IFNgamma may be involved in down-regulation of GVHD via a negative feedback loop.48 Mice receiving transplanted cells from IFNgamma knockout donors develop accelerated lethal aGVHD, also supporting a negative feedback role for IFNgamma .14,15

As an alternative explanation for our findings, the in vivo stimulus provided by BMT conditioning may well have a different relationship to the Intron1 polymorphism to that shown by the in vitro response to mitogens.19,20 Macrophage activation as a result of recipient tissue damage by TBI and cytotoxic chemotherapy, in concert with IFNgamma production by T and natural killer cells, is pivotal in early conditioning-induced cytokine release.49-51 This network of cytokine interactions initiating aGVHD is more complex than direct in vitro T-cell activation by mitogens.52 The IFNgamma Intron1 polymorphism results indeed suggest that associations of cytokine gene polymorphic alleles with in vivo clinical outcomes do not necessarily correlate well with in vitro production data.

Recipients of BMT who were homozygous for the low producer IL-6-174C allele had milder aGVHD overall, consistent with the postulated genetic protection from IL-6 release. Chronic GVHD showed significant association with IL-6 genotype, largely to that of recipient but with a trend in respect to donor genotype, despite smaller numbers of available donor samples. The gene dosage effect of possession of the IL-6-174G allele, with homozygotes developing more GVHD, both in terms of aGVHD severity and cGVHD incidence, is also supportive of a true biologic relationship between genetic background and GVHD, especially with reference to in vitro and in vivo production data.28 Intriguingly, there has been little previous examination of the potential role of IL-6 in cGVHD, and the association of functionally associated IL-6 genotypes with cGVHD may point toward future areas of study.

The IL-6 3' minisatellite polymorphism did not associate with GVHD despite a degree of linkage of the IL-6-174C allele to the F allele at the 3' (AT)-rich minisatellite. This may suggest that the promoter region polymorphism is more functionally relevant in BMT. In examining the relationship between IL-6 genotype and GVHD in other cohorts it will be important to bear in mind the differing allele frequencies of the IL-6 polymorphisms in various populations. The IL-6-174C allele is uncommon in Afro-Caribbean populations,28 a group some have suggested have a higher incidence of GVHD.53,54

The relatively small numbers of patients in our study do not allow strong conclusions regarding the relative impact of cytokine genotype-associated GVHD risk with respect to established risk factors such as age, gender mismatch, or CMV status, but would suggest that they are potentially of a similar magnitude (odds ratio between 3 and 5). The absence of an overall relationship between additional immunosuppresssion with MTX/steroids and GVHD probably reflects the targeted use of prophylaxis in our BMT unit.55 The confirmation of significant association of acute and chronic GVHD with these cytokine genotypes suggests that further studies should be undertaken in a prospective fashion. Ideally the association of these cytokine gene polymorphisms should also be tested in other settings, such as mismatched or unrelated donor BMT, and with different prophylaxis regimens, to examine the relative importance of cytokine gene polymorphisms together with other parameters including high-resolution HLA typing, minor histocompatibility antigens, and established clinical risk factors for GVHD. It will be important to examine potential relationships of cytokine genotype with relapse, because an immunomodulatory factor that reduces alloreactivity against host tissues may also do so against residual host malignancy. Cytokines mediate and regulate other BMT complications such as septic shock, multiorgan dysfunction, and interstitial pneumonitis; studies are ongoing in relation to some of these complications.

Relationships demonstrated thus far support the attempted construction, in a prospective fashion, of a GVHD risk index integrating clinical and immunogenetic factors (related to both histocompatibility and nonhistocompatibility including cytokine genotyping). Any risk index will ideally attempt to accurately assign GVHD risk to all patients, but optimizing their prophylaxis may depend on considerations of other factors. Hence, clinical use of cytokine genotype data via an aGVHD risk index may not only be dependent on transplant type (sibling/unrelated, matched/mismatched, marrow/stem cells/cord) but also may be influenced by the indication for BMT and other clinical risk elements.

In conclusion, our findings confirm the principle that the recipient response is critical in BMT outcome, particularly in relation to aGVHD, and that this response involves a substantial genetic component. In addition to reconfirming the association of TNF and IL-10 gene polymorphism alleles, 2 new candidate polymorphisms in IFNG and IL6 genes are shown to associate with aGVHD severity, and in the case of IL6 with cGVHD incidence. Multivariable analysis suggests that these genetic polymorphisms may confirm a similar magnitude of increased GVHD risk to certain other established risk factors, but further studies are clearly needed, ideally involving other BMT groups such as those with mismatched and unrelated donors. Combination of recipient aGVHD severity-associated genotypes increases discrimination as to aGVHD severity. These findings would support the construction of BMT- and prophylaxis-specific genotypic aGVHD risk indices, which could be tested prospectively in combination with established GVHD risk factors. PCR-based cytokine genotyping of recipients and donors could easily be performed alongside HLA typing, when donor options are being assessed and decisions regarding prophylaxis made. A recipient GVHD risk index including cytokine genotype could be used as a guide to more individually tailored GVHD prophylaxis, particularly in combination with other risk factors.


    Footnotes

Submitted June 7, 2000; accepted April 10, 2001.

Supported by a grant from the Leukaemia Research Fund (to J.C.) and the Tyneside Leukaemia Research Fund (to A.M.D.).

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

Reprints: James Cavet, Department of Haematology, Royal Victoria Infirmary, Victoria Road, Newcastle upon Tyne, NE1 4LP, United Kingdom; e-mail: james.cavet{at}ncl.ac.uk.


    References
Top
Abstract
Introduction
Patients, materials, and...
Results
Discussion
References

1. Hagglund H, Bostrom L, Remberger M, Ljungman P, Nilsson B, Ringden O. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant. 1995;16:747-753[Medline] [Order article via Infotrieve].

2. Barrett AJ, van Rhee F. Graft-versus-leukaemia. Baillieres Clin Haematol. 1997;10:337-355[Medline] [Order article via Infotrieve].

3. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75:2459-2464[Abstract/Free Full Text].

4. Ferrara JL, Cooke KR, Pan L, Krenger W. The immunopathophysiology of acute graft-versus-host-disease [review]. Stem Cells. 1996;14:473-489[Abstract].

5. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute graft-versus-host disease [review]. Transplantation. 1997;64:553-558[CrossRef][Medline] [Order article via Infotrieve].

6. Roncarolo MG. The role of interleukin-10 in transplantation and GVHD. In: Ferrara JLM,Deeg HJ,Burakoff SJ, eds. Graft-Versus-Host Disease. 2nd ed. New York: Marcel Dekker; 1997:693-715.

7. Korholz D, Kunst D, Hempel L, et al. Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19:691-695[CrossRef][Medline] [Order article via Infotrieve].

8. Holler E, Roncarolo MG, Hintermeier-Knabe R, et al. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25:237-241[CrossRef][Medline] [Order article via Infotrieve].

9. Velardi A, Varese P, Terenzi A, et al. Lymphokine production by T-cell clones after human bone marrow transplantation. Blood. 1989;74:1665-1672[Abstract/Free Full Text].

10. Niederwieser D, Herold M, Woloszczuk W, et al. Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation. 1990;50:620-625[Medline] [Order article via Infotrieve].

11. Carayol G, Bourhis JH, Guillard M, et al. Quantitative analysis of T helper 1, T helper 2, and inflammatory cytokine expression in patients after allogeneic bone marrow transplantation: relationship with the occurrence of acute graft-versus-host disease. Transplantation. 1997;63:1307-1313[CrossRef][Medline] [Order article via Infotrieve].

12. Dickinson AM, Sviland L, Hamilton PJ, et al. Cytokine involvement in predicting clinical graft-versus-host disease in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 1994;13:65-70[Medline] [Order article via Infotrieve].

13. Brok HP, Heidt PJ, van der Meide PH, Zurcher C, Vossen JM. Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol. 1993;151:6451-6459[Abstract].

14. Murphy WJ, Welniak LA, Taub DD, et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest. 1998;102:1742-1748[Medline] [Order article via Infotrieve].

15. Yang YG, Qi J, Sykes M. IFN-gamma downmodulates graft-versus-host disease while mediating graft-versus-leukaemic effects. Blood. 1999;94:635a.

16. Imamura M, Hashino S, Kobayashi H, et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant. 1994;13:745-751[Medline] [Order article via Infotrieve].

17. Ochs LA, Blazar BR, Roy J, Rest EB, Weisdorf DJ. Cytokine expression in human cutaneous chronic graft-versus-host disease. Bone Marrow Transplant. 1996;17:1085-1092[Medline] [Order article via Infotrieve].

18. Ruiz-Linares A. Dinucleotide repeat polymorphism in the interferon-gamma (IFNG) gene. Hum Mol Genet. 1993;2:1508[Free Full Text].

19. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet. 1999;26:1-3[CrossRef][Medline] [Order article via Infotrieve].

20. Reynard MP, Turner D, Wadhwa M, Bird C, Navarrete CV. The influence of an IFN-gamma gene microsatellite on IFN-gamma production [abstract]. Immunology. 2000;61:S138.

21. Awad M, Pravica V, Perrey C, et al. CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum Immunol. 1999;60:343-346[CrossRef][Medline] [Order article via Infotrieve].

22. Asderakis A, Sankaran D, Pravica V. High producer interferon gamma (IFNg) and interleukin 10 (IL-10) genotype is associated with increased frequency of acute rejection episodes in kidney transplant recipients. British Transplantation Society 1st Annual Congress; 1998.

23. Symington FW, Symington BE, Liu PY, Viguet H, Santhanam U, Sehgal PB. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation. 1992;54:457-462[Medline] [Order article via Infotrieve].

24. Abdallah AN, Boiron JM, Attia Y, Cassaigne A, Reiffers J, Iron A. Plasma cytokines in graft vs host disease and complications following bone marrow transplantation. Hematol Cell Ther. 1997;39:27-32[CrossRef][Medline] [Order article via Infotrieve].

25. Tanaka J, Imamura M, Kasai M, Sakurada K, Miyazaki T. Cytokine gene expression after allogeneic bone marrow transplantation. Leuk Lymphoma. 1995;16:413-418[Medline] [Order article via Infotrieve].

26. Lange A, Klimczak A, Karabon L, Suchnicki K. Cytokines, adhesion molecules (E-selectin and VCAM-1) and graft-versus-host disease. Arch Immunol Ther Exp 1995;43:99-105.

27. Bowcock AM, Kidd JR, Lathrop GM, et al. The human "interferon-beta 2/hepatocyte stimulating factor/interleukin-6" gene: DNA polymorphism studies and localization to chromosome 7p21. Genomics. 1988;3:8-16[CrossRef][Medline] [Order article via Infotrieve].

28. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102:1369-1376[Medline] [Order article via Infotrieve].

29. Marshall SE, McLaren AJ, Haldar NA, Bunce M, Morris PJ, Welsh KI. Cytokine and cytokine receptor polymorphisms and acute rejection after renal transplantation [abstract]. Immunology. 2000;61:S2.

30. Bowcock AM, Ray A, Erlich H, Sehgal PB. Rapid detection and sequencing of alleles in the 3' flanking region of the interleukin-6 gene. Nucleic Acids Res. 1989;17:6855-6864[Abstract/Free Full Text].

31. Murray RE, McGuigan F, Grant SF, Reid DM, Ralston SH. Polymorphisms of the interleukin-6 gene are associated with bone mineral density. Bone. 1997;21:89-92[Medline] [Order article via Infotrieve].

32. Linker-Israeli M, Wallace DJ, Prehn J, et al. Association of IL-6 genes with systemic lupus erythematosus (SLE) and with elevated IL-6 expression. Genes Immun. 1999;1:45-52[CrossRef][Medline] [Order article via Infotrieve].

33. Middleton PG, Taylor PRA, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood. 1998;92:3943-3948[Abstract/Free Full Text].

34. Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host-disease in HLA-matched sibling bone marrow transplants. Blood. 1999;94:3941-3946[Abstract/Free Full Text].

35. Kogler G, Wilke M, Middleton PG, et al. Cytokine gene polymorphism of the recipient influences the development of acute graft versus host disease in HLA mismatched cord blood transplants [abstract]. Bone Marrow Transplant. 2000;25:S4.

36. Sankaran D, Asderakis A, Ashraf S, et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int. 1999;56:281-288[CrossRef][Medline] [Order article via Infotrieve].

37. Dickinson AM, Sviland L, Carey P, et al. Skin explant culture as a model for cutaneous graft-versus-host disease in humans. Bone Marrow Transplant. 1988;3:323-329[Medline] [Order article via Infotrieve].

38. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986;314:729-735[Abstract].

39. Udalova IA, Nedospasov SA, Webb GC, Chaplin DD, Turetskaya RL. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics. 1993;16:180-186[CrossRef][Medline] [Order article via Infotrieve].

40. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304[Medline] [Order article via Infotrieve].

41. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1989;4:247-254[Medline] [Order article via Infotrieve].

42. Turner DM, Grant SC, Lamb WR, et al. A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation. 1995;60:1113-1117[Medline] [Order article via Infotrieve].

43. Eskdale J, Wordsworth P, Bowman S, Field M, Gallagher G. Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus [published erratum appears in Tissue Antigens 1997 Dec;50(6):699]. Tissue Antigens 1997;49:635-639[Medline] [Order article via Infotrieve].

44. Weissensteiner T, Lanchbury JS. TNFB polymorphisms characterize three lineages of TNF region microsatellite haplotypes. Immunogenetics. 1997;47:6-16[CrossRef][Medline] [Order article via Infotrieve].

45. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab. 1995;80:41-45[Abstract].

46. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet. 1999;8:93-97[Abstract/Free Full Text].

47. Carlens S, Ringden O, Remberger M, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998;22:755-761[CrossRef][Medline] [Order article via Infotrieve].

48. Brok HP, Vossen JM, Heidt PJ. Interferon-gamma-mediated prevention of graft-versus-host disease: development of immune competent and allo-tolerant T cells in chimeric mice. Bone Marrow Transplant. 1997;19:601-606[CrossRef][Medline] [Order article via Infotrieve].

49. Xun C, Brown SA, Jennings CD, Henslee-Downey PJ, Thompson JS. Acute graft-versus-host-like disease induced by transplantation of human activated natural killer cells into SCID mice. Transplantation. 1993;56:409-417